PALISADE BIO, INC.

For the period ended Sep 30, 2026. Filed Nov 10, 2026.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2026 · Filed Nov 10, 2026

PALI$1.13-5.0%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Stockholders’ Equity

(in thousands, except share amounts)

Preferred Stock · Common Stock · AdditionalPaid-inCapital · AccumulatedDeficit · TotalStockholders'Equity
Shares · Amount · Shares · Amount
Balance, June 30, 2026	200,000	$2		173,595,201		$1,735		$292,910		$(172,899)		$121,748
Net loss	—	—		—		—		—		(14,623)		(14,623)
Stock-based compensation expense and related charges	—	—		—		—		5,065		—		5,065
Issuance of common stock for vesting of restricted stock units			675,224		7		(7)		—		—
Issuance of common stock in connection with exercise of warrants	—	—		133		—		—		—		—
Issuance of common stock in connection with Crohn's and Colitis Foundation Agreement (Note 5)	—	—		172,413		2		248		—		250
Balance, September 30, 2026	200,000	$2		174,442,971		$1,744		$298,216		$(187,522)		$112,440

Preferred Stock · Common Stock · AdditionalPaid-inCapital · AccumulatedDeficit · TotalStockholders'Equity
Shares · Amount · Shares · Amount
Balance, June 30, 2025	200,000	$2	4,800,247	$48	$143,528	$(140,958)	$2,620
Net loss	—	—	—	—	—	(2,868)	(2,868)
Stock-based compensation expense and related charges	—	—	—	—	47	—	47
Issuance of common stock in connection with July 2025 Warrant Inducement, net of issuance costs of $9,330 (Note 5)	—	—	4,318,905	43	3,370	—	3,413
Balance, September 30, 2025	200,000	$2	9,119,152	$91	$146,945	$(143,826)	$3,212

Condensed Consolidated Statements of Stockholders’ Equity

(in thousands, except share amounts)

Preferred Stock · Common Stock · AdditionalPaid-inCapital · AccumulatedDeficit · TotalStockholders'Equity
Shares · Amount · Shares · Amount
Balance, December 31, 2025	200,000	$2	159,444,017	$1,594	$280,509	$(152,725)	$129,380
Net loss	—	—	—	—	—	(34,797)	(34,797)
Stock-based compensation expense and related charges	—	—	—	—	14,147	—	14,147
Issuance of common stock to vendors	—	—	10,000	—	—	—	—
Issuance of common stock for vesting of restricted stock units	—	—	705,022	7	(7)	—	—
Issuance of common stock under Employee Stock Purchase Plan	—	—	13,031	—	20	—	20
Issuance of common stock in connection with exercise of warrants	—	—	12,369,886	123	32	—	155
Issuance of common stock in connection with Crohn's and Colitis Foundation Agreement (Note 5)	—	—	364,130	4	559	—	563
Issuance of common stock in connection with stock purchase agreement, net of issuance costs of $28 (Note 5)	—	—	1,536,885	16	2,956	—	2,972
Balance, September 30, 2026	200,000	$2	174,442,971	$1,744	$298,216	$(187,522)	$112,440

Preferred Stock · Common Stock · AdditionalPaid-inCapital · AccumulatedDeficit · TotalStockholders'Equity
Shares · Amount · Shares · Amount
Balance, December 31, 2024	200,000	$2	2,768,646	$27	$143,407	$(135,944)	$7,492
Net loss	—	—	—	—	—	(7,882)	(7,882)
Stock-based compensation expense and related charges	—	—	—	—	185	—	185
Issuance of common stock under Employee Stock Purchase Plan	—	—	4,601	—	3	—	3
Issuance of common stock in connection with exercise of warrants	—	—	2,027,000	21	(20)	—	1
Issuance of common stock in connection with July 2025 Warrant Inducement, net of issuance costs of $9,330 (Note 5)	—	—	4,318,905	43	3,370	—	3,413
Balance, September 30, 2025	200,000	$2	9,119,152	$91	$146,945	$(143,826)	$3,212

Condensed Consolidated Stateme

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.